Kodiak Sciences Inc. (KOD) Stock

Kodiak Sciences Inc. (KOD) is a Healthcare stock trading at $36.09 (as of 2026-06-18), with a market capitalization of $2.30B and a trailing P/E of -8.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company developing and commercializing therapeutics for retinal diseases. Its lead candidate, KSI-301, is an anti-VEGF antibody biopolymer in Phase IIb/III for wet AMD and other retinal indications, including diabetic macular edema and related conditions.

Valuation — source: SEC EDGAR (first-party)
Price	$36.09
Market Cap	$2.30B
P/E Ratio	-8.8
EV / EBITDA	-9.8
Price / Book	20.49
DCF Value (model)	$-34.18
DCF Upside vs Price	-194.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.52M
Net Margin	-5091.1%
Return on Equity	-205.8%
Current Ratio	3.54
Revenue Growth (YoY)	-59.5%
EPS Growth (YoY)	29.0%
FCF Growth (YoY)	16.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.92 (distress)

Valuation vs Sector & Industry
Stock P/E	-8.8
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-142.0%
vs Industry	-151.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BAKER BROS. ADVISORS LP ($759.32M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Victor Perlroth
Employees	109
Country	US
IPO Date	2018-10-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.